Valbiotis SAS - Asset Resilience Ratio

Latest as of June 2025: 27.04%

Valbiotis SAS (ALVAL) has an Asset Resilience Ratio of 27.04% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Valbiotis SAS (ALVAL) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€5.38 Million
≈ $6.29 Million USD Cash + Short-term Investments

Total Assets

€19.89 Million
≈ $23.26 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Valbiotis SAS's Asset Resilience Ratio has changed over time. See Valbiotis SAS (ALVAL) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Valbiotis SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Valbiotis SAS worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €5.38 Million 27.04%
Short-term Investments €0.00 0%
Total Liquid Assets €5.38 Million 27.04%

Asset Resilience Insights

  • Very High Liquidity: Valbiotis SAS maintains exceptional liquid asset reserves at 27.04% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Valbiotis SAS Industry Peers by Asset Resilience Ratio

Compare Valbiotis SAS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Orkla ASA
OL:ORK
Packaged Foods 4.19%
New Hope Dairy Co Ltd
SHE:002946
Packaged Foods 2.26%
Yankershop Food Co Ltd
SHE:002847
Packaged Foods 4.97%
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
Packaged Foods 6.41%
Yantai China Pet Foods Co Ltd
SHE:002891
Packaged Foods 0.35%
Xinjiang Guannong Fruit & Antler Group Co Ltd
SHG:600251
Packaged Foods 5.13%
Xiamen Kingdomway Group Co
SHE:002626
Packaged Foods 4.11%
Zhejiang Huatong Meat Products Co Ltd
SHE:002840
Packaged Foods 3.78%

Annual Asset Resilience Ratio for Valbiotis SAS (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Valbiotis SAS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 40.33% €7.91 Million
≈ $9.24 Million
€19.61 Million
≈ $22.92 Million
+32.62pp
2023-12-31 7.70% €2.57 Million
≈ $3.00 Million
€33.31 Million
≈ $38.94 Million
+5.71pp
2022-12-31 1.99% €541.00K
≈ $632.49K
€27.17 Million
≈ $31.77 Million
+0.09pp
2021-12-31 1.90% €541.00K
≈ $632.49K
€28.48 Million
≈ $33.29 Million
-1.24pp
2020-12-31 3.14% €660.00K
≈ $771.61K
€21.00 Million
≈ $24.55 Million
-8.98pp
2019-12-31 12.12% €1.82 Million
≈ $2.13 Million
€15.02 Million
≈ $17.55 Million
-73.47pp
2018-12-31 85.59% €10.19 Million
≈ $11.91 Million
€11.91 Million
≈ $13.92 Million
+2.21pp
2017-12-31 83.38% €10.60 Million
≈ $12.39 Million
€12.71 Million
≈ $14.86 Million
+50.80pp
2016-12-31 32.57% €529.00K
≈ $618.46K
€1.62 Million
≈ $1.90 Million
+1.94pp
2015-12-31 30.63% €355.01K
≈ $415.05K
€1.16 Million
≈ $1.35 Million
--
pp = percentage points

About Valbiotis SAS

PA:ALVAL France Packaged Foods
Market Cap
$25.61 Million
€21.91 Million EUR
Market Cap Rank
#24293 Global
#396 in France
Share Price
€0.93
Change (1 day)
-0.54%
52-Week Range
€0.55 - €1.23
All Time High
€10.54
About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more